Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

JHOP - December 2020 Vol 10, No 6

Desensitization Permits Continued Trastuzumab and Ado-Trastuzumab Emtansine Therapy After Hypersensitivity Reaction

Anna Kempke, PharmD, BCOP, BCPS; Shawna Kraft, PharmD, BCOP; Mariana Castells, MD, PhD; Rajan Ravikumar, MD; Catherine Van Poznak, MD

Original Article

Outcomes for Patients Receiving Ibrutinib with or without Antifungal Therapy

Kori Daniels, PharmD, BCOP; Arpita Gandhi, PharmD, BCOP; Locke Bryan, MD; Amber Clemmons, PharmD, BCOP

The Safety Profile of Mini-Dose Methotrexate for Graft-versus-Host Disease Prophylaxis: Is There a Place for Folinic Acid Rescue?

Loriel J. Solodokin, PharmD, BCOP; Amir Steinberg, MD, FACP; Erin Moshier, MS

Evaluation of Inpatient Oral Chemotherapy: An Academic Medical Center Experience

Vincent J. Cascone, PharmD, BCOP; Kane M. Hosmer, PharmD, BCOP; Zahra Mahmoudjafari, PharmD, BCOP; David W. Henry, MS, RPh, BCOP, FASHP; Dennis W. Grauer, MS, PhD

Vaccination Rates in Patients with Hematologic Cancers After Hematopoietic Stem-Cell Transplant: A Single-Center Retrospective Study

Hiba Ahmad, PharmD, BCOP; Sarah Perreault, PharmD, BCPS, BCOP; Dayna McManus, PharmD, BCPS-AQ ID; Francine Foss, MD; Iris Isufi, MD; Stuart Seropian, MD; Jeffrey Topal, MD

HOPA Abstracts

HOPA 2020 Abstracts, Part IV

FDA Oncology Update

FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer

Danyelza First Drug FDA Approved for High-Risk Neuroblastoma in the Bone and Bone Marrow

Gavreto, a New RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Onureg FDA Approved for Adults with AML in Remission

Gavreto Now Approved for Thyroid Cancer with RET Fusions

Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer

Keytruda Approved for Relapsed or Refractory Classical Hodgkin Lymphoma

Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma